This year, science celebrates mapping 90% of the human proteome, an endeavor that has been achieved by the Human Proteome Project (HPP). Technology Networks explored the journey to this successful feat by speaking with Professor Emanuel Petricoin.Petricoin is a professor and co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University. Petricoin's research focus is on the development of cutting-edge microproteomic technologies, identifying and discovering biomarkers for early stage disease detection, developing novel bioinformatic approaches for protein-protein interaction analysis and creating nanotechnology tools for increased analytical detection, drug delivery and monitoring. He is one of the founding members of the Human Proteome Organization (HUPO).Molly Campbell (MC): As one of the co-founders of HUPO, how do you feel about the news that ~90% of the human proteome has now been mapped?Emanuel Petricoin (EP): Its a great achievement! One of the major objectives when we first launched HUIPO was to simply understand the nature and existence of the human proteome. But the development of the catalogue is really only the beginning, and of course those last 10% may be exceedingly difficult to categorize and uncover; they are the lowest abundance analytes which may contain the most important biochemical information as far as human disease and the biomarkers that everyone is after are concerned.
We need to couple new advances in sample preparation to concentrate and be able to bring them into the sensitivity range of mass spectrometry. Moreover, and critically, there are a massive number of post-translational modifications (PTMs) of the proteome and it is really these PTMs that make all of the difference in biology and disease. We really dont have a clue as to that proteome! This is what is difficult about proteomics, it's not simply a list of proteins but it is their expression level, location, activation state and who is talking to who, as the proteome is a dynamic, physically interconnected network of interacting molecules with fine-tuned orchestration of location and amounts. Even with this great achievement, it is simply a list and like a list of parts for a 747 aircraft, it doesnt tell you anything about how the aircraft is put together, how it operates and most importantly how to fly it. But, before you can do anything, you have to know the parts list. This is what the field has achieved, and it is fantastic but just a start we need to take the parts list and construct the instruction manual, and that is going to take a huge amount of continued effort.
MC: The blueprint of the human proteome comes almost twenty years after the completion of the Human Genome Project. During this time, do you think attitudes towards the proteomics field have changed? If so, how?EP: Absolutely. I think there is a real and important shift to proteomics now a beyond genomics orientation. I think some of this is the limitations that are being seen in the narrow actionability landscape of genomics in many diseases, notably cancer, as well as recognition that genomics-stratified patients do not effectively capture many of the responders and non-responders in many targeted therapy efforts. We still need a massive injection of new discoveries of highly sensitive and specific biomarkers for disease detection. HUPOs efforts here provide that catalyst and I think you are seeing more and more examples of biomarker signatures comprised of both genomic and proteomic markers for more accurate and sensitive disease detection. Moreover, I think that there is a re-focused interest by the field of molecular diagnostics and precision medicine on the potential for true synergy between proteomics and genomic based profiling for better clinical outcomes and better biomarker signatures for detection and treatment of human diseases.
MC: The HPP is divided into the C-HPP and the B/D-HPP. What are each of these subcategories, and why is the project divided in this way?EP: These efforts underscore the unbelievable complexity of the human proteome- in fact it illustrates the fact that a simple parts list, while important, is not even close to being enough; as they say, while the DNA is the information archive, its the proteins that do all of the work and it's all about what proteins are expressed, how much is expressed, where they are expressed, at what time they are expressed, in what isoform they are expressed and to what levels (phosphorylated, myristolated, glycolsylated etc.) and in what cell type are they expressed. You may actually argue that there should be a further subdivision of other sub-categories within each of the disease subgroups in the B/D -HPP and C-HPP categories!
MC: Confident detection of the human proteome has risen from 69.8% in 2011 to 90.4% in 2020. How has this been achieved?EP: Massive improvements in mass spectrometry instrumentation and mass accuracy and the computational informatics side together have led to this along with better enrichment and fractionation methods for better sample input integrity.
MC: Are there some proteins that we may never be able to map? If so, why is this?
EP: Perhaps it will take quite a while, but I can't imagine that we can be so dogmatic to say NEVER- science is always improving and getting better and better. Right now, it is a product of these 10% being extremely low abundance and having extremely short half-lives and mass spectrometry still not being analytically sensitive enough to see these markers.
MC: How can the data from the HPP be used in a clinical context? What barriers exist to translating the research from lab to the clinic?EP: Well, that is the elephant in the room, isnt it? The same was said after the human genome was mapped. Patients stood at the announcement and said so what? How does this information and list of genes help me today or tomorrow with my cancer? The same can rightfully be said here how does a simple list of proteins help a cancer patient today? The field needs to be very transparent and thoughtful about how it conveys the impact of the achievement to everyday impact on humans and society. It will take years and decades more effort to take the aggregate of this proteomic data to translate into well performing clinical grade diagnostics/therapeutics that impact patients at the bedside and it is not like we didnt already have most of the 90% already much of this has been had for years and we still havent taken a vast majority of it to new biomarkers/treatments/drug targets that physicians use to manage care.
Emanuel Petricoin was speaking to Molly Campbell, Science Writer, Technology Networks.
See more here:
Mapping the Human Proteome: A Conversation With Professor Emanuel Petricoin - Technology Networks
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated... - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022